Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$30.50 -1.1%	$31.35	$24.10 ▼ $62.53	$2.89B	0.28	845,032 shs	480,466 shs
HCM HUTCHMED	$15.43 -1.8%	$14.56	$11.51 ▼ $21.50	$2.74B	0.52	99,966 shs	39,187 shs
REPL Replimune Group	$9.49 -0.2%	$8.74	$6.44 ▼ $17.00	$732.71M	0.63	889,776 shs	849,942 shs
VKTX Viking Therapeutics	$26.28 -0.6%	$26.73	$18.92 ▼ $81.73	$2.97B	0.65	4.05 million shs	2.28 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	-1.12%	-6.74%	-1.25%	-11.02%	-31.00%
HCM HUTCHMED	-6.43%	-6.71%	+17.33%	-2.90%	-12.14%
REPL Replimune Group	-3.26%	-6.12%	+21.15%	-17.30%	+21.77%
VKTX Viking Therapeutics	-1.97%	-9.30%	-7.03%	-12.11%	-49.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	3.5287 of 5 stars	3.5	0.0	3.7	2.7	2.5	0.0
HCM HUTCHMED	1.338 of 5 stars	2.0	2.0	0.0	2.0	0.0	1.9
REPL Replimune Group	4.5339 of 5 stars	3.6	3.0	4.5	3.7	2.5	0.6
VKTX Viking Therapeutics	4.437 of 5 stars	4.5	1.0	4.7	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	144.44% Upside
HCM HUTCHMED	2.00	Hold	$19.00	23.14% Upside
REPL Replimune Group	3.14	Buy	$20.83	119.53% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	231.64% Upside

Current Analyst Ratings Breakdown

Latest REPL, VKTX, HCM, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/8/2025	VKTX Viking Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$30.00
3/26/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.04M	2,745.88	N/A	N/A	$14.29 per share	2.13
HCM HUTCHMED	$630.20M	4.27	$0.28 per share	54.69	$4.43 per share	3.48
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.57	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest REPL, VKTX, HCM, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
HCM HUTCHMED	0.08	2.83	2.70
REPL Replimune Group	0.17	7.95	7.95
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
HCM HUTCHMED	8.82%
REPL Replimune Group	92.53%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	4.60%
HCM HUTCHMED	3.60%
REPL Replimune Group	8.80%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	89.32 million	Optionable
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

REPL, VKTX, HCM, and CRNX Headlines

Recent News About These Companies

MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 18 at 5:59 AM | marketbeat.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

June 16 at 10:31 AM | zacks.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Handelsbanken Fonder AB

June 16 at 3:48 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmA

June 13, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Rises on Expected Developments

June 12, 2025 | insidermonkey.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 12, 2025 | zacks.com

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

June 12, 2025 | finance.yahoo.com

Harbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 12, 2025 | marketbeat.com

Viking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)

June 12, 2025 | americanbankingnews.com

Brokers Issue Forecasts for VKTX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Analysts Issue Forecasts for VKTX FY2026 Earnings

June 11, 2025 | marketbeat.com

Wesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 11, 2025 | marketbeat.com

Viking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)

June 10, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?

June 10, 2025 | marketbeat.com

Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?

June 9, 2025 | msn.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from Brokerages

June 9, 2025 | americanbankingnews.com

1 Stock Down 34% This Year to Buy and Hold

June 8, 2025 | fool.com

39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLC

June 6, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Analysts

June 6, 2025 | marketbeat.com

Profit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, VKTX, HCM, and CRNX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.50 -0.35 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$30.51 +0.01 (+0.03%)

As of 07:09 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$15.43 -0.28 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$15.55 +0.12 (+0.77%)

As of 04:42 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Replimune Group NASDAQ:REPL

$9.49 -0.02 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.99 +0.50 (+5.32%)

As of 07:57 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$26.28 -0.15 (-0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$26.32 +0.04 (+0.15%)

As of 07:56 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time